儿童手足口病患者行临床营养支持与人干扰素α-2b喷雾剂治疗的疗效

Objective To investigate the clinical efficacy of human interferon α-2b spray combined with individualized parenteral nutrition support in children with hand-foot-mouth disease(HFMD). Methods A total of 120 pediatric patients with HFMD admitted to our hospital' s pediatric department from February 2023 to December 2024 were enrolled. According to the principle of random number table method, they were divided into a control group(treated with human interferon α-2b spray alone) and an experimental group(treated with human interferon α-2b spray combined with individualized parenteral nutrition support), with 60 cases in each group. Results The overall effective rate in the experimental group was 95.00%, which was significantly higher than that in the control group(83.33%)(P<0.05). The time required for symptom relief in the experimental group was significantly shorter than that in the control group(P<0.05). Additionally, the levels of interleukin-6(IL-6), interleukin-4(IL-4), white blood cell(WBC) and highsensitivity C-reactive protein(hs-CRP) in the experimental group were significantly lower than those in the control group. Furthermore, the levels of immunoglobulin G(IgG), immunoglobulin A(IgA) and total protein(TP) were significantly higher than those in the control group, and the differences were statistically significant(P>0.05). During the treatment period and a 28-day follow-up, two drug-related adverse events(3.33%) occurred in each group, with no statistically significant difference between the groups(P>0.05). All adverse events met the CTCAE 5.0 grade II criteria, and symptoms resolved within 48 hours after discontinuation of the medication. Conclusion The combination of human interferon α-2b spray and individualized parenteral nutrition support demonstrates significant improvements in clinical outcomes for children with HFMD, effectively shortens symptom relief time, inhibits inflammatory responses, and exhibits good safety.